About Rhelixa
Rhelixa is a company based in Chiyoda (Japan) founded in 2015. Rhelixa has raised $5.58 million across 2 funding rounds from investors including Mitsubishi Corporation, Kirin and Joyo Bank. Rhelixa operates in a competitive market with competitors including Helix, Strand Life Sciences, Benchling, Genuity Science and Inpharmatica, among others.
- Headquarter Chiyoda, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.58 M (USD)
in 2 rounds
-
Latest Funding Round
$3.37 M (USD), Series B
Aug 20, 2024
-
Investors
Mitsubishi Corporation
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rhelixa
Rhelixa has successfully raised a total of $5.58M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $3.37 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rhelixa
Rhelixa has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Mitsubishi Corporation, Kirin and Joyo Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support for early-stage deep tech ventures is provided.
|
Locked | Locked | Locked | |
|
Venture capital services are provided to support startups and innovation.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Rhelixa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rhelixa
Investment portfolio details for Rhelixa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rhelixa
Detailed financials for Rhelixa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rhelixa Comparisons
Peer comparison for Rhelixa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rhelixa
Rhelixa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helix, Strand Life Sciences, Benchling, Genuity Science and Inpharmatica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
AI-based omics data analysis solutions are provided to researchers.
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
Detailed competitors of Rhelixa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rhelixa
Complete news archive for Rhelixa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rhelixa
Rhelixa was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Rhelixa is headquartered in Chiyoda, Japan. It is registered at Chiyoda, Tokyo, Japan.
Ryo Nakaki is the current CEO of Rhelixa.
Rhelixa is a funded company, having raised a total of $5.58M across 2 funding rounds to date.
Rhelixa was established in 2015 in Chiyoda City, Japan, within the genomics sector. An integrated platform for genomic analysis is offered, where core algorithms are applied to process comprehensive epigenome data from next-generation sequencers. Services for analyzing next-generation sequencing data are also delivered, supporting research and applications in epigenetics and related fields. Operations focus on technology-driven solutions for data interpretation in biotechnology.
Rhelixa's top competitors include Strand Life Sciences, Helix and Benchling.
Rhelixa has 8 investors. Key investors include Mitsubishi Corporation, Kirin, Joyo Bank, Leave a Nest Capital, and JFC.